316.67
1.83 (0.58%)
| Previous Close | 314.84 |
| Open | 316.92 |
| Volume | 194,371 |
| Avg. Volume (3M) | 477,643 |
| Market Cap | 14,283,908,096 |
| Price / Earnings (TTM) | 12.62 |
| Price / Earnings (Forward) | 11.24 |
| Price / Sales | 4.81 |
| Price / Book | 1.93 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2025 - 4 Aug 2025 |
| Profit Margin | 40.44% |
| Operating Margin (TTM) | 48.19% |
| Diluted EPS (TTM) | 25.11 |
| Quarterly Revenue Growth (YOY) | 17.20% |
| Quarterly Earnings Growth (YOY) | 5.10% |
| Total Debt/Equity (MRQ) | 2.94% |
| Current Ratio (MRQ) | 5.46 |
| Operating Cash Flow (TTM) | 1.41 B |
| Levered Free Cash Flow (TTM) | 825.79 M |
| Return on Assets (TTM) | 12.93% |
| Return on Equity (TTM) | 19.94% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | United Therapeutics Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | -3.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Average | -0.70 |
|
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Value |
| % Held by Insiders | 1.75% |
| % Held by Institutions | 100.69% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 415.00 (UBS, 31.05%) | Buy |
| Median | 330.00 (4.21%) | |
| Low | 295.00 (Wells Fargo, -6.84%) | Hold |
| Average | 355.43 (12.24%) | |
| Total | 4 Buy, 3 Hold | |
| Avg. Price @ Call | 293.66 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 13 Aug 2025 | 415.00 (31.05%) | Buy | 309.72 |
| 30 Jun 2025 | 385.00 (21.58%) | Buy | 287.35 | |
| HC Wainwright & Co. | 31 Jul 2025 | 400.00 (26.31%) | Buy | 274.70 |
| Wells Fargo | 31 Jul 2025 | 295.00 (-6.84%) | Hold | 274.70 |
| Morgan Stanley | 10 Jul 2025 | 328.00 (3.58%) | Hold | 300.16 |
| JP Morgan | 08 Jul 2025 | 330.00 (4.21%) | Buy | 294.42 |
| B of A Securities | 11 Jun 2025 | 315.00 (-0.53%) | Hold | 276.47 |
| Cantor Fitzgerald | 02 Jun 2025 | 405.00 (27.89%) | Buy | 325.48 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MAHON PAUL A | - | 310.66 | -11,000 | -3,417,260 |
| Aggregate Net Quantity | -11,000 | |||
| Aggregate Net Value ($) | -3,417,260 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 310.66 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MAHON PAUL A | Officer | 21 Aug 2025 | Automatic sell (-) | 11,000 | 310.66 | 3,417,260 |
| MAHON PAUL A | Officer | 21 Aug 2025 | Option execute | 11,000 | - | - |
| Date | Type | Details |
|---|---|---|
| 29 Aug 2025 | Announcement | United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference |
| 01 Aug 2025 | Announcement | United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program |
| 30 Jul 2025 | Announcement | United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results |
| 16 Jul 2025 | Announcement | United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025 |
| 24 Jun 2025 | Announcement | United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver |
| 23 Jun 2025 | Announcement | United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |